Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 3, 2003, Pages 1107-1111

  Baudin, E ^a   Cao, C Do ^a   Cailleux, A F ^a   Leboulleux, S ^a   Travagli, J P ^a   Schlumberger, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THYROGLOBULIN; THYROID HORMONES; THYROID NEOPLASMS;

EID: 0037342073     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021365     Document Type: Article

References (22)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
2. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463
3. Grebe SK, Hay ID 1997 Follicular cell-derived thyroid carcinomas. In: Arnold A, ed. Endocrine neoplasms. Boston: Kluwer Academic Publishers; 91-140
4. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID 1998 Therapeutic controversy: the use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83:4195-4203
5. Schlumberger M, Baudin E 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249-252
6. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 85:175-178
7. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GS, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
9. Robbins RJ, Turtle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625
10. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498
11. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A 1985 Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 23:405-411
12. Sherman SI, Tielens ET, Sostre S, Wharam Jr MD, Ladenson PW 1994 Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629-634
13. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A 1987 Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888-1891
14. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 29:1790-1794
15. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488-1492
16. 131I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097
17. Hedinger C, Williams ED, Sobin LH 1988 Histological typing of thyroid tumours. International histological classification of tumours. World Health Organization, vol 11, ed 2. Berlin: Springer-Verlag
18. 1992 Thyroid gland (ICD-OC73). In: Hermanek P, Sobin LH, eds. TNM classification of malignant tumors, 4th ed, 2nd revision. International union against cancer. Berlin: Springer-Verlag; 35-37
19. Mc Dougall IR 1997 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 7:669-672
20. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA 2002 Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 87:1521-1526
21. 131I) treatment of hyperthyroidism. In: Freeman LM, Miller JM, eds. Nuclear medicine annual. New York: Raven Press; 265-290
22. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605